Sugi Predict

Sugi Predict / Compounds / SCHEMBL25317167

SCHEMBL25317167

SCHEMBL25317167

C[C@@H](COc1ccc2c(c1)CCC(=O)N2C)N1CCC2(CC1)C(=O)Nc1ccc(C#N)cc12

nearest known ligand 0.42

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ TRIM24 O15164 2/20 0.42
▸ CYP11B1 P15538 2/20 0.39
▸ CYP11B2 P19099 2/20 0.39
▸ MAOA P21397 4/20 0.37
▸ MAOB P27338 4/20 0.37
▸ PGR P06401 5/20 0.36
▸ DRD2 P14416 1/20 0.35
▸ CYP1A2 P05177 1/20 0.34
▸ GABRG2 P18507 1/20 0.34
▸ GABRB3 P28472 1/20 0.34
▸ GABRA5 P31644 1/20 0.34
▸ IP6K1 Q92551 1/20 0.34
▸ ALK Q9UM73 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30506913 1.00 TRIM24 (0.42) TRIM24CYP11B1CYP11B2MAOAMAOB
SCHEMBL25314493 1.00 TRIM24 (0.42) TRIM24CYP11B1CYP11B2MAOAMAOB
SCHEMBL30507216 1.00 TRIM24 (0.42) TRIM24CYP11B1CYP11B2MAOAMAOB
SCHEMBL25314491 1.00 TRIM24 (0.42) TRIM24CYP11B1CYP11B2MAOAMAOB
SCHEMBL26024619 0.92 MAOA (0.36) TRIM24CYP11B1CYP11B2MAOAMAOB
SCHEMBL25933820 0.89 TRIM24 (0.42) TRIM24CYP11B1CYP11B2MAOAMAOB
SCHEMBL25316176 0.89 TRIM24 (0.42) TRIM24CYP11B1CYP11B2MAOAMAOB
SCHEMBL30507099 0.89 TRIM24 (0.42) TRIM24CYP11B1CYP11B2MAOAMAOB
SCHEMBL30507071 0.87 ALK (0.43) CYP11B1CYP11B2MAOAMAOBPGR
SCHEMBL25316415 0.87 ALK (0.43) CYP11B1CYP11B2MAOAMAOBPGR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250282781-A1 APOL1 INHIBITORS AND METHODS OF USE HERCULES CAPITAL, INC., AS AGENT 2025-09-11 — — US disclosed
US-12344610-B2 APOL1 inhibitors and methods of use MAZE THERAPEUTICS, INC. (US) 2025-07-01 — — US disclosed
US-20240400565-A1 APOL1 INHIBITORS AND METHODS OF USE HERCULES CAPITAL, INC., AS AGENT 2024-12-05 — — US disclosed
US-11976067-B2 APOL1 inhibitors and methods of use MAZE THERAPEUTICS, INC. (US) 2024-05-07 — — US disclosed
US-20230265096-A1 APOL1 INHIBITORS AND METHODS OF USE HERCULES CAPITAL, INC., AS AGENT 2023-08-24 — — US disclosed
WO-2023141432-A2 APOL1 INHIBITORS AND METHODS OF USE MAZE THERAPEUTICS, INC. (US) 2023-07-27 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230265096-A1 APOL1 INHIBITORS AND METHODS OF USE APOL1, APOB, LDLR TRIM24 2709/4885CYP11B1 331/4885CYP11B2 515/4885
US-12344610-B2 APOL1 inhibitors and methods of use APOL1, APOB, PON1 TRIM24 2604/4885CYP11B1 303/4885CYP11B2 457/4885
US-11976067-B2 APOL1 inhibitors and methods of use APOL1, APOB, LDLR TRIM24 2709/4885CYP11B1 331/4885CYP11B2 515/4885
US-20250282781-A1 APOL1 INHIBITORS AND METHODS OF USE APOL1, APOB, PON1 TRIM24 2604/4885CYP11B1 303/4885CYP11B2 457/4885
US-20240400565-A1 APOL1 INHIBITORS AND METHODS OF USE APOL1, APOB, PON1 TRIM24 2604/4885CYP11B1 303/4885CYP11B2 457/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.